Adicet Bio News Today

Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 6,940,000 shares, a drop of 9.6% from the April 30th total of 7,680,000 shares. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio […]

Adicet Bio (NASDAQ:ACET – Get Free Report) and Eterna Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability. Insider and Institutional Ownership 83.9% of Adicet […]

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor,...

StockNews.com upgraded shares of Adicet Bio (NASDAQ:ACET – Free Report) to a sell rating in a report published on Monday. A number of other analysts also recently issued reports on the stock. HC Wainwright restated a buy rating and set a $10.00 price target on shares of Adicet Bio in a report on Wednesday, May […]

Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target […]

Adicet Bio, Inc. (NASDAQ:ACET – Free Report) – Research analysts at Wedbush dropped their Q2 2024 EPS estimates for shares of Adicet Bio in a research report issued on Wednesday, May 15th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.37) per share for the quarter, down from their previous forecast of […]

Adicet Bio, Inc. (NASDAQ:ACET – Free Report) – Investment analysts at Wedbush cut their Q2 2024 earnings per share estimates for Adicet Bio in a research note issued on Wednesday, May 15th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.37) per share for the quarter, down from their previous estimate of […]

Wedbush reiterated their outperform rating on shares of Adicet Bio (NASDAQ:ACET – Free Report) in a report issued on Tuesday, Benzinga reports. Wedbush currently has a $5.00 price target on the stock. A number of other research firms also recently issued reports on ACET. HC Wainwright reiterated a buy rating and set a $10.00 price […]

Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in...

22.04.2024 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data ... Seite 1